Obesity focused Kailera appoints Nur Nicholson as CTO
US clinical-stage biopharma Kailera Therapeutics (Nasdaq: KLRA), focused on elevating the next era of obesity care, today announced the appointment of Nur Nicholson as chief technology officer (CTO), effective August 31, 2026.
“We are excited to welcome Nur as an executive at such a pivotal moment for Kailera,” said Ron Renaud, president and chief executive of Kailera. “As we advance ribupatide injection through global Phase III trials, look to begin our Phase III program for ribupatide oral in the first half of next year, and continue the development of our broader pipeline, Nur’s track record of building resilient manufacturing networks and leading organizations through commercial launch will be instrumental to our success,” he added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze